Fortress Biotech (FBIO) vs Rani Therapeutics (RANI)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Fortress Biotech (FBIO) has outperformed Rani Therapeutics (RANI) over the past year, losing 26.6% versus a loss of 68.6%. Over five years, FBIO leads with a -95.5% price change compared with -98.3% for RANI. Fortress Biotech is the larger company by market cap ($64.1 million vs $59.0 million), about 1.1 times the size, while Rani Therapeutics is growing revenue faster (+58.9% vs +9.7%).
Fortress Biotech converts more of its revenue into profit, with a net margin of 10.8% versus -1817.1%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | FBIO | RANI |
|---|---|---|
| Share price | $1.90 | $0.5111 |
| Market cap | $64.11M | $59.03M |
| 1-day change | +7.34% | -11.97% |
| YTD return | -48.09% | -62.14% |
| 1-year return | -26.64% | -68.64% |
| 5-year return | -95.52% | -98.34% |
| P/E ratio (TTM) | 0.83 | — |
| EPS (TTM) | $2.30 | $-0.06 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $63.26M | $1.63M |
| Revenue growth (YoY) | +9.69% | +58.85% |
| Net income (latest FY) | $6.82M | $-29.67M |
| Gross margin | 66.92% | — |
| Operating margin | -111.00% | -2345.99% |
| Net margin | 10.77% | -1817.09% |
| 52-week high | $4.53 | $1.69 |
| 52-week low | $1.64 | $0.502 |
| Distance from 52-week high | -58.06% | -69.76% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +163.16% | +1308.73% |
| Average volume | 281.49K | 545.67K |
| Shares outstanding | 33.74M | 115.49M |
| Employees | 78 | 69 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- FBIO has outperformed RANI by 42.0 percentage points over the past year.
- Fortress Biotech is more profitable, keeping 10.8 cents of every revenue dollar as net income versus -1817.1 cents for Rani Therapeutics.
- Rani Therapeutics grew revenue faster in its latest fiscal year (+58.85% vs +9.69%).
About Fortress Biotech
FBIO stock →Fortress Biotech, Inc., together with its subsidiaries, operates as a biopharmaceutical company in the United States and internationally. The company offers Emrosi, a minocycline hydrochloride extended-release capsule for the treatment of rosacea; Qbrexza a medicated cloth towelette for the treatment of axillary hyperhidrosis; Accutane, an oral isotretinoin drug for the treatment of severe recalcitrant nodular acne; Amzeeq, a minocycline topical foam for the treatment of lesions of non-nodular moderate to severe acne vulgaris; Zilxi, a minocycline topical foam for the treatment of lesions of rosacea; Exelderm, an antifungal cream for topical use; Targadox, an oral doxycycline drug for the therapy of severe acne; Luxamend, a water-based emulsion for the treatment of superficial wounds, minor cuts or scrapes, dermal ulcers, donor sites, first and second-degree burns, and radiation dermatitis; and UNLOXCYT, a death-ligand 1 blocking antibody for the treatment of metastatic cutaneous squamous cell carcinoma.
Health Care · Biotechnology: Pharmaceutical Preparations · 78 employees
About Rani Therapeutics
RANI stock →Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company, focusing on technologies to enable the administration of biologics and drugs orally for patients, physicians, and healthcare systems with a alternative to painful injections in the United States.
Health Care · Biotechnology: Pharmaceutical Preparations · 69 employees
FBIO vs RANI FAQ
Which is bigger, Fortress Biotech or Rani Therapeutics?
Fortress Biotech (FBIO) is larger, with a market capitalization of $64.11M compared with $59.03M for Rani Therapeutics (RANI).
Which stock has performed better over the past year, FBIO or RANI?
FBIO returned -26.64% over the past 12 months, compared with -68.64% for RANI (price return, excluding dividends). Past performance does not predict future results.
Are Fortress Biotech and Rani Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.